GI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, P. R. China.
School of Physics, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.
Nat Commun. 2021 Jun 15;12(1):3651. doi: 10.1038/s41467-021-23923-1.
Extracellular cytokines are enriched in the tumor microenvironment and regulate various important properties of cancers, including autophagy. However, the precise molecular mechanisms underlying the link between autophagy and extracellular cytokines remain to be elucidated. In the present study, we demonstrate that IL-6 activates autophagy through the IL-6/JAK2/BECN1 pathway and promotes chemotherapy resistance in colorectal cancer (CRC). Mechanistically, IL-6 triggers the interaction between JAK2 and BECN1, where JAK2 phosphorylates BECN1 at Y333. We demonstrate that BECN1 Y333 phosphorylation is crucial for BECN1 activation and IL-6-induced autophagy by regulating PI3KC3 complex formation. Furthermore, we investigate BECN1 Y333 phosphorylation as a predictive marker for poor CRC prognosis and chemotherapy resistance. Combination treatment with autophagy inhibitors or pharmacological agents targeting the IL-6/JAK2/BECN1 signaling pathway may represent a potential strategy for CRC cancer therapy.
细胞外细胞因子在肿瘤微环境中富集,并调节癌症的各种重要特性,包括自噬。然而,自噬与细胞外细胞因子之间联系的确切分子机制仍有待阐明。在本研究中,我们证明了 IL-6 通过 IL-6/JAK2/BECN1 途径激活自噬,并促进结直肠癌 (CRC) 的化疗耐药性。在机制上,IL-6 触发 JAK2 和 BECN1 之间的相互作用,其中 JAK2 在 Y333 处使 BECN1 磷酸化。我们证明 BECN1 Y333 磷酸化对于 BECN1 激活和 IL-6 诱导的自噬至关重要,通过调节 PI3KC3 复合物的形成。此外,我们研究了 BECN1 Y333 磷酸化作为 CRC 预后不良和化疗耐药的预测标志物。自噬抑制剂或针对 IL-6/JAK2/BECN1 信号通路的药理学药物联合治疗可能代表 CRC 癌症治疗的一种潜在策略。